[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK3551629T3 - Oxabicycloheptaner til modulering af immunrespons - Google Patents

Oxabicycloheptaner til modulering af immunrespons Download PDF

Info

Publication number
DK3551629T3
DK3551629T3 DK17879038.2T DK17879038T DK3551629T3 DK 3551629 T3 DK3551629 T3 DK 3551629T3 DK 17879038 T DK17879038 T DK 17879038T DK 3551629 T3 DK3551629 T3 DK 3551629T3
Authority
DK
Denmark
Prior art keywords
oxabicycloheptanes
modulation
immune response
immune
response
Prior art date
Application number
DK17879038.2T
Other languages
English (en)
Inventor
John S Kovach
Zhengping Zhuang
Sze Chun Winson Ho
Herui Wang
Rongze Lu
Original Assignee
Lixte Biotechnology Inc
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lixte Biotechnology Inc, Us Health filed Critical Lixte Biotechnology Inc
Application granted granted Critical
Publication of DK3551629T3 publication Critical patent/DK3551629T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DK17879038.2T 2016-12-08 2017-12-08 Oxabicycloheptaner til modulering af immunrespons DK3551629T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662497949P 2016-12-08 2016-12-08
US201762465001P 2017-02-28 2017-02-28
US201762545373P 2017-08-14 2017-08-14
PCT/US2017/065270 WO2018107004A1 (en) 2016-12-08 2017-12-08 Oxabicycloheptanes for modulation of immune response

Publications (1)

Publication Number Publication Date
DK3551629T3 true DK3551629T3 (da) 2024-02-12

Family

ID=62491355

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17879038.2T DK3551629T3 (da) 2016-12-08 2017-12-08 Oxabicycloheptaner til modulering af immunrespons

Country Status (13)

Country Link
US (1) US20200069680A1 (da)
EP (2) EP4324477A3 (da)
JP (2) JP7246309B2 (da)
KR (2) KR20240042151A (da)
CN (2) CN116585480A (da)
AU (1) AU2017370731B2 (da)
BR (1) BR112019011627A2 (da)
CA (1) CA3046515A1 (da)
DK (1) DK3551629T3 (da)
ES (1) ES2970913T3 (da)
IL (2) IL290857B2 (da)
MX (1) MX2019006694A (da)
WO (1) WO2018107004A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2984267T3 (es) 2013-04-09 2024-10-29 Lixte Biotechnology Inc Formulaciones de oxabicicloheptanos y oxabicicloheptenos
MX2021012440A (es) 2015-05-15 2022-06-28 Lixte Biotechnology Inc Farmacos precursores de oxabicicloheptanos.
KR102723511B1 (ko) 2019-08-13 2024-10-28 주식회사 엘지에너지솔루션 전극 스크랩 재활용 방법 및 이를 이용한 전극 제조 방법
WO2024097784A2 (en) * 2022-11-03 2024-05-10 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for treating refractory cancers

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166531A1 (en) * 2001-02-16 2003-09-04 Genetics Institute, Inc. Methods for modulating an immune response by modulating the interaction between CTLA4 and PP2A
EP2124550B1 (en) * 2007-02-06 2017-04-19 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
US8227473B2 (en) * 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
GB0903325D0 (en) 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
EP2867239A4 (en) * 2012-06-29 2015-12-23 Lixte Biotechnology Inc OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES
EP2870161B1 (en) * 2012-06-29 2018-08-08 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of reperfusion injury
ES2984267T3 (es) * 2013-04-09 2024-10-29 Lixte Biotechnology Inc Formulaciones de oxabicicloheptanos y oxabicicloheptenos
US20160264593A1 (en) 2013-11-15 2016-09-15 John S. Kovach Protein phosphatase inhibitors that cross the blood brain barrier
EP3157336A4 (en) * 2014-06-20 2018-01-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer
WO2016040877A1 (en) * 2014-09-12 2016-03-17 Lixte Biotechnology, Inc. Human dosing of phosphatase inhibitor
KR20170138477A (ko) * 2015-04-17 2017-12-15 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물
MX2021012440A (es) 2015-05-15 2022-06-28 Lixte Biotechnology Inc Farmacos precursores de oxabicicloheptanos.

Also Published As

Publication number Publication date
US20200069680A1 (en) 2020-03-05
IL290857B (en) 2022-11-01
AU2017370731A1 (en) 2019-07-04
EP3551629A4 (en) 2020-07-29
CA3046515A1 (en) 2018-06-14
CN110234647B (zh) 2023-05-23
BR112019011627A2 (pt) 2019-11-12
CN116585480A (zh) 2023-08-15
IL290857A (en) 2022-04-01
KR20240042151A (ko) 2024-04-01
AU2017370731B2 (en) 2022-06-02
CN110234647A (zh) 2019-09-13
EP4324477A2 (en) 2024-02-21
EP4324477A3 (en) 2024-05-22
IL267134B (en) 2022-04-01
JP2023036999A (ja) 2023-03-14
KR20190098995A (ko) 2019-08-23
JP7246309B2 (ja) 2023-03-27
MX2019006694A (es) 2019-08-21
EP3551629B1 (en) 2023-11-15
WO2018107004A1 (en) 2018-06-14
EP3551629A1 (en) 2019-10-16
IL267134A (en) 2019-08-29
JP2020502094A (ja) 2020-01-23
IL290857B2 (en) 2023-03-01
ES2970913T3 (es) 2024-05-31

Similar Documents

Publication Publication Date Title
DK3512850T3 (da) Inhibitorer af menin-mll-interaktionen
DK3468966T3 (da) Inhibitorer af menin-mll-interaktionen
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3096741T3 (da) Fremgangsmåde til fremstillingen af hybridosomer
DK3463248T3 (da) Anordnnger til anvendelse af lægemiddelanordninger
DK3325443T3 (da) Fremgangsmåde til fremstilling af pridopidin
DK3174858T3 (da) Fremgangsmåde til fremstilling af pyrazoler
DK3300500T3 (da) Triazolagonister af apj-receptoren
DK3556775T3 (da) Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter
DK3262071T3 (da) Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
DK3317400T3 (da) Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter
DK3126373T3 (da) Fremgangsmåde til fremstilling af amg 416
DK3186244T3 (da) Dioxolananaloger af uridin til behandling af cancer
DK3507408T3 (da) Fremgangsmåde til fremstilling af nonwoven
DK3452507T3 (da) Tau-immunoterapi
DK3529233T3 (da) Fremgangsmåde til fremstilling af 3-alkylsulfanyl-2-chlor-n-(1-alkyl-1h-tetrazol-5-yl)-4-trifluoromethyl-benzamider
DK3668358T3 (da) Indretning til tilberedning af varme drikke
DK3280408T3 (da) Fremgangsmåde til fremstilling af dicycloplatin
DK3233813T3 (da) Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser
DK3166611T3 (da) Fremgangsmåde til fremstilling af 4-alkoxy-3-hydroxypicolinsyrer
DK3479159T3 (da) Moduleret fabry-pérot
DK3177931T3 (da) Fremgangsmåde til bestemmelse af stoffers evne til at binde til analytaktive steder
DK3544416T3 (da) Applikation af væsker
DK3463001T3 (da) Kogegrej
IL290857A (en) Oxabicycloheptanes for immune response modulation